EXHIBIT A

The following provides details for support for the amendments to Table 4 of the Specification and illustrates the amendments introduce no new matter.

In particular, the following provides sequence information as shown in originally filed Table 4 followed by the matching portion of preliminarily amended Table 4 (showing the proposed amendments).

Specification as Filed for SEQ ID NOS: 49 and 54:

Underlining in the original specification denotes support for amendments.

Re-	Epi-	_					
gion	tope	Cone	Libs	Frankwork §	CDR 3	Francework 4	
¥µ		C15 C9	2	QVELQOSCAELVE FCASVEL SCHTSJYSFT	GITTOVOCCHTYAACT	Waystiviass	← SEQ ID NO: 49
		iDS Ci	2	E ++ 0 VE - ++ 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0			as originally filed
		\$25					
		186 109	2	Q	←SEO ID NO: 54		
		103 1037	$\frac{2}{2}$	E-QEPGK-SQ-L6-7-7V7I-	as originally filed		

Specification as Amended for SEQ ID NOS: 49 and 54:

			Sequence ²		
V _K R	egion		į.		
Epit	ope i	Framework 1	CDR 1	Framework 2	CDE 3
		Pranework 3	CDR3	Framework 4	Seq ID No
€9	1	QVKLQQSGARLVRPGASVKLSCKTSGYSFT	SYMM	WVKQGPGQGLEWIG	Mihponseirpnokpen
		MATLITYDESSSTAYMQLSSFTSEDSAVYYCAR	GIYYVYDGGN YY AMDY	WGQGTTVTVSS	49
			<u>YY</u>		
		<u>G</u>			
109	2	QVqLkQSGAELVRPGVSVXi3CX - SGYtYi	DYAVR	WYKQshaksLEWIG	vistyygdadyNpkFkg
ĺ	[kwfl/Tvnmssmfaywelprlfssdsaiyycar	Rgkg AMDY	weqetevty85	54

EXHIBIT A

Specification as Filed for SEQ ID NO: 63:

Re- gion	Epi- tope	Clone	Lib*	Francourk i	CDR 1
	2	161	3	Kartakegestas egoekkt egoleg blibe	DXX#S
		1F1: C39:	2		N-6
		C28	3	Q=Q=Q=======X=====Q=====A====A=====	¥
		263	2		S-2
		30.3	2	~XvvxvX-vvvLX	8-A
		3F4	2		S.A ←SEQ ID N
		3114	2	XX	عدي as original

Specification as Amended for SEQ ID NO: 63:

394	2	2 E : \$a63	ราลสร	WvRQtPehRLEWVA	TISDOGTĚTYYUDAVKO
į	1	RFTISRIMAKHULYLQHSHLHSEDIAMYYCUR	alpyšky Dy	WGGGTSVTVSS	63

Specification as Filed for SEQ ID NOS: 68 and 69:

Re- gion	Epi- tope	Clone	Lib	Framework 3	a	OR i
	3	183	2	evoloeskiizvvo poeslälskaasiptips	SYAM	
		1C6	2	QIaviQavovoanvaarraavraavra	*****	
		2138	2	VKLVESGP-L-KRSQSLSLTCTVTGYSIT-	D~ A8R	
		165	2	QQXELAYYMXYY	~~WTT	← SEQ ID NO: 68
		1146	2	control Marie Control Section	WELL WALL	← SEQ ID NO: 69

as originally filed

Specification as Amended for SEQ ID NOS: 68 and 69:

1G5 2	<pre>gVQLQqSGselVOPGaSvksSCkASGyTFt</pre>	#Ywtt S Elgd	aMDy	WVkQrPGgGLEWig WCQCTsVIVSS	dTypgagatnynekfKa KS	
3H6 Z	<u>K</u> EVQLQqSGaelV Q FGaSVkmsCkASGyTFt karltvDtSasTaYmSlsSLtsEDsAVYYCAE	Tiwit S Flad	aMDV	WVkQrPGqQLEWig WGQGTEVIVSS	dlypDagatnynekfKa	

EXHIBIT A

Specification as Filed for SEQ ID NOS: 72-80:

Clone	Libř	Framework i	CDR i	Francwork 3	Francework 4
Ciš	4	Diblios paingas kervinto	PASS	OVPIRATORSCOTE YSLTIERMEREDEATYYC	PRECENTATION SEQ ID NO: 72
C9	1		****		••• SEQ ID NO: 73
195	2	**************************************		В подучения поставляющий в профессия	G1 SEQ ID NO: 74
Ci	Ţ	********	****		SEQ ID NO: 75
525	ř	معالا محجب سيعيم والإستانية والمستعددة	• ¥ £	Looging and service and service for some	SEQ ID NO: 76
196	2	SIAV-L.QRA-18-	ra-esv		SEQ ID NO: 70
1C9	2	SLAV-L-CRA-IS-	ra - esv	MALLER DFT REVIOLATION	SEQ ID NO: 78
SEX.	2			and and an area and area and a second and a	SEQ ID NO: 79
1G7	2		AANN.	1 - A	SEQ ID NO: 79
					as originally file

Specification as Amended for SEQ ID NOS: 72-80:

V Regi Epit	ope l				
Clone	Lib	Framework 1	CDR I	Framework 2	CDR 2
		Francwork 3	CDR 3	Framework 4	Seq ID
C15	1	DIELTOSPAIMSASPGERVIMTC	SASS SVSHMY	WYQQKPGSSPRLLIY	DYSNLAS
	1	<u>G</u> ₩PIRFSGSGSGTSYSLTISRMEAED9ATYYC	QQWSSYPFT	FGSGTKLELKE	72
C9	1	DIGLTOSPAIMSESPGEKVILTC	SASS SVSymh	wfQQKPGtSPkpwlY	sysneas
	1	G ⊕VPaRFSGSGSGTSYSUTISSVRAEDaATYYC	QQySqYPlT	FGeGTKLEiKR	73
1D5	2	DIELTOSPAIMAASPGEKVIITC	SASSs iSaSnlh	WYCOKsetapkpwlY	gtsnlas
	<u>i</u>	G ₩V₽VRFSGSGSGTSYSLTISSMEAEDaATYYC	QQMqSYPlT	POGGTELBIER	74
ci	1	Dieltospaimsaspgekvimte	SASS SVSyMY	WYQQKFGSSFRLLIY	DISNLAS
		⊆ ⊕vpvkfsgsgsgtsysltigkmeaedaatyyc	QQWSSYFIT	PGaGTKLELKR	75
\$25	1	DIELTQSPAlmaASPGEKVIITC	SvSSs iSsSmlh	WYQQKsGtSPkpwIY	gtsnlas
]	G ♥VPVRF8GSGSGTSYSL/FISSMEAEDDATXYC	QQWSSYPIT	FGaGTKLEiKR	76
186	5	DIELTQSPAslavSlGqralisC	rafesvdsygnäimh s	MAÖÖKBEĞDBYITIA	rasmLes
		G⊕iPaR#SGSGStTdftbTinpvEAdDvATYYC	- QQsnedPpT	FGaGTKLELKR	77
1.09	2	DIELTQSFAslavSlGqraLisC	ra¥esvdsygnSfMh	WYQQKFGqpFkLLIY	raSNLeS
	.]	⊆ †iPaRFSGSGSrTdEtLTIngvEAdOvATYYC	S Wanedry?	fgg f3a0tk leikr	78
1E8	2	Dieltospaimsaspgekvintc	SASS SVSymb	WYQQKsGtSFkrwIY	DTSKLAS
		<u>G</u>	QQWSS6917	FGagtklelke	79
lG7	2	DibltQspaimsaspgemvintC	Sass Svsymh	WYQQXsGtSPkrwIY	DYSKLAS
		G €VPaRFSGSGSGTSYSLTISSNEAED8ATYYC	QQWSSnPl7	FGaGTKLELKR	80

EXHIBIT A

Specification as Filed for SEQ ID NOS: 81-88:

Clone	Libs	Framework i	CDR 1	CDR 3	Francework 4
A!	2	DIBLTON VASLAVSLOGRATISC	rasesvosythuemh O	MARTHAL	FACTORIAL SEQ ID NO:
(3)	2	20000200 Tarroans	*****		SEQ ID NO:
39	1	·	nangannaa H anaa Jee	*****	SEQ ID NO:
28	£.	**************		SF-	
G5.	2		\$5.48 \$\$\display\$	RSSY	SSINGE SEQ ID NO:
C3	2	IMSA-P-EXXIII-		R55Y	SEQ ID NO:
} :\$	2	-TIMEA-P-EXVINI-	S8 SV-Y-Y	Wasy-P-	SEQ ID NO:
114	2	A THE STATE OF THE	8- VSS-YL	WSSY-P-	SEO ID NO:

Specification as Amended for SEQ ID NOS: 81-88:

			<u>H</u>	<u>G</u> <u>I</u>	
141	[2	dieltqspaslavslgqkatisc	rasesvosygnsfm s	MAÖÖKEGÖSEKTTIA	Lasmles
		gyparfsgsgskidfiltidpyeaddaatyyc	QQ UESYPET NN	EDPYT FGGGTKLESKR	81
191	2	DIELTQSPESLAVSLGQRATISC	RASESVOSYGNSFMH	MAÖÖKBGÖBBKTTIA	Laskles
	3	CVPARPSCSCSRIDFTLTIDPVEADDAATYYC	ÇÇ -CƏYFİ T <u>NNE</u> DP <u>Y</u>	<u>g</u> <u>I</u> Fo s cikle s kr	82
C39	1	DIELTQSPASLAVSLG:RATISC	RASESVOSYGBSFMH	WYQQK9GQPBKLLIY	LASNLES
	i	GYPARFSGSGSRTDFTL/TIDPVEADDAATYYC	QQ waaxri t	PG#GTKLE£YR	83
	••••	•	NNEDPY	<u>G</u> <u>I</u>	
C25	1	DIELTOSPASLAVSLGORATISC	RASESVDSYGhSFMg	MAGOKAGOABKTTIA	rASNLEp
		GifarfsGSGSgtDftutInfYEADDvATYYC	QQ xesyri t	FGSGTKLE L KR	64
·			SNEDPF	<u>I</u>	
295	2	DIELTÇSFAimsaSpGekytttC	sass sysymc	WfQQKPGtsPkLwIY	sisnlas
		CVFARPSGSGSGTBYBLTISTMEAGDAATTYC	QQ amadPy T	9GS/GdgagnKS	85
			RSSYPY		
303	2	DIEUTOSFAimsaSpGekvtttC	RASESVOSYGHSFRG	WfQCEPGtsPkLwTY	stSNLaS
	1	GVFARFSGSGSGTeysLTIszmEAeDAATYYC	QQ anedPy T	FGSGdqagnKR	8.6
	·		RSSYPY		
384	12	<u>M</u> DtBL/YOSFAimsaSpGekvt⊕tC	eass sysumu	E WYCOKPGssPrtLIY	desneas
26.4	- 1 "	QVPVRFSGSGSGTsysLTIsrmEAeDAATYYC	OCWSSm ply YE	5 ~~	87
384	2	DIELTOSFAimsaSpGekytatC M	RASSS vssSylG	WYQQKPGssPrLLIY	desneas
		CVFVRFSGSGSgTsysLTIsmmEAeDAATYYC	QQMSS ari t	FGSGTKL/##KR	98
·····	*************		<u>YPP</u>	<u>I</u>	*

EXHIBIT A

Specification as Filed for SEQ ID NOS: 94 and 95:

***	·····		•
~~	Sequence ^b		
Otto	CDR 2	Framework 3	i.
****			SEC ID NO. 04
18/3	Sainlas	gvpsepegscegts <u>vel</u> tes sveakdaatyvc	← SEQ ID NO: 94
268	£T	- 11A	◆ SEQ ID NO: 95
A	ALC:	door	as originally filed

Specification as Amended for SEQ ID NOS: 94 and 95:

SL

183	2	DIELTQSPASMSASPGEKVTMTC	Katss Vsssylh	NYQQKSGASPKLWIY	SASNLAS
	İ	GVFSRFSGSGSGTSY LG TISSVEAEDAATYYC	QQYIGYFYT	PGGGTKLEIKR	94
258	2	DIELTQSPttmaASPGEKiTiTC	sAsSS igSnYLH	wygokogispkliiy	*tsnlas
		CVP&RFSCSCSCTSYSLTIgs#EAEDvATYYC	QQgssiPYT	PGGGTKLEIKR	<u>R</u> 95

EXHIBIT B

The following illustrates that the amendments to the claims to correct the sequence identifiers do not introduce new matter.

The relevant parts of Table 11 on page 85-88, paragraph [0241] of the Specification <u>as</u> <u>originally filed</u> are reproduced below.

[0241] Table 11 amino acid sequences for affinity matured and/or modified antibodies.

	Heavy (Chains			
	Clone	Framework 1	CDR1	Framework 2	CDR2
	huC25	QVQLQESGGGLVQPGGSLRLSC AASGFTFS (SEQ ID	DYYMY (SEQ ID NO:87)	WVRQAPGKGLEW VA(SEQ ID	TISDGGSYTYYPD SVKG(SEQ ID
*****		The state of the s	·····	www.minon.mmino.mmino.mm	and the second second
ļ	······································	NO:86)		NO:88)	NO:89)

. . .

Heavy Ch	ains cont'd			
	Framework 3	CDR3	Framework 4	
huC25	RFTISRDNSKNTLYLQMNSLRA EDTAMYYCSR(SEQ ID	YRYDDAMDY(S EQ ID	WGQGTLVTVSS(SEQ ID	
	NO:126)	NO:127)	NO:128)	

• • •

Light Cha	ins			
Clone	Framework 1	CDR1	Framework 2	CDR2
huC25	EIVLTQSPATLSLSPGERATIS	RASESVDSYGH	WYQQKPGQAPRL	RASNLEP(SEQ
	C(SEQ ID NO:156)	SFMQ(SEQ ID NO:157)	LIY(SEQ ID NO:158)	ID NO:159)

. .

Light Chains cont'd.				
Clone	Framework 3	CDR3	Framework 4	
huC25	GIPARFSGSGSGTDFTLTISSL	QQSNEDPFT(S	FGQGTKVEIKR (
	RPEDFAVYYC (SEQ ID NO:196)	EQ ID NO:197)	SEQ ID NO:198)	

EXHIBIT B

The relevant parts of Table 11 as amended pursuant to the **Preliminary Amendment** filed April 19, 2004 are reproduced below.

At pages 85-88, amend Table 11 as follows:

[0241] Table 11 amino acid sequences for affinity matured and/or modified antibodies.

Heavy Cl	nains			
Clone	Framework 1	CDRI	Framework 2	CDR2
huC25	QVQLQESGGGLVQPGGSLRLSC AASGFTFS (SEQ ID NO:86138)	DYYMY(SEQ ID NO: 87<u>139</u>)	WVRQAPGKGLEW VA(SEQ ID NO:88140)	TISDGGSYTYYPD SVKG(SEQ ID NO: 89 141)

. . .

Heavy Chains cont'd				
	Framework 3	CDR3	Framework 4	
huC25	RFTISRDNSKNTLYLQMNSLRA EDTAMYYCSR(SEQ ID NO: 126 178)	YRYDDAMDY(S EQ ID NO:127179)	WGQGTLVTVSS (SEQ ID NO: 128 180)	

. .

Light Ch	·			
Clone	Framework 1	CDRI	Framework 2	CDR2
huC25	EIVLTQSPATLSLSPGERATIS C(SEQ ID NO: 156 208)	RASESVDSYGH SFMQ(SEQ ID NO: 157 209)	WYQQKPGQAPRL LIY(SEQ ID NO: 158 210)	RASNLEP(SEQ ID NO: 159 211)

• •

Light Cha	iins cont'd.			
Clone	Framework 3	CDR3	Framework 4	
huC25	GIPARFSGSGSGTDFTLTISSL EPEDFAVYYC (SEQ ID NO: 196 248)	QQSNEDPFT (SEQ ID NO: 197 249)	FGQGTKVEIKR (SEQ ID NO: 198 250)	

EXHIBIT B

The sequence information of SEQ ID NOS: 139, 141, 179, 209, 211, and 249, as shown in the enclosed Sequence Listing, as well as their one letter code sequences are as follows.

As shown in the Sequence Listing: <210> 139 <211> 5 <212> PRT <213> Artificial Sequence	One-Letter Code:	Sequence in the Specification as Amended in the Preliminary Amendment:
<220> <223> single chain antibody fragment <400> 139 Asp Tyr Tyr Met Tyr 1 5	SEQ ID NO: 139 DYYMY	DYYMY (SEQ ID NO: 87139)
<210> 141 <211> 17 <212> PRT <213> Artificial Sequence		
<220> <223> single chain antibody fragment <400> 141 Thr Ile Ser Asp Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val Lys 1 5 10 15 Gly	SEQ ID NO: 141 TISDGGSYTYYPDSVKG	TISDGGSYTYYPD SVKG(SEQ ID NO: 89 141)
<210> 179 <211> 9 <212> PRT <213> Artificial Sequence		
<220> <223> single chain antibody fragment <400> 179 Tyr Arg Tyr Asp Asp Ala Met Asp Tyr 1 5	SEQ ID NO: 179 YRYDDAMDY	YRYDDAMDY(S EQ ID NO: 127 179)

EXHIBIT B

<210> 209 <211> 15 <212> PRT <213> Artificial Sequence <220> RASESVDSYGH <223> single chain antibody fragment SFMQ(SEQ ID <400> 209 SEQ ID NO: 209 NO: 457209) Arg Ala Ser Glu Ser Val Asp Ser Tyr Gly His RASESVDSYGHSFMQ Ser Phe Met Gln 10 15 <210> 211 <211>7 <212> PRT <213> Artificial Sequence <223> single chain antibody fragment <400> 211 RASNLEP (SEQ SEQ ID NO: 211 Arg Ala Ser Asn Leu Glu Pro ID NO: 159211) **RASNLEP** 5 <210> 249 <211>9 <212> PRT <213> Artificial Sequence <220> <223> single chain antibody fragment QQSNEDPFT (SEQ ID SEQ ID NO: 249 <400> 249 NO: 197249) **QQSNEDPFT** Gln Gln Ser Asn Glu Asp Pro Phe Thr